BioXcel Therapeutics, Inc is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology.

Source: https://www.americanbankingnews.com/2023/01/03/artemis-investment-management-llp-cuts-stake-in-bioxcel-therapeutics-inc-nasdaqbtai.html

Finally, The Goldman Sachs Group lifted their target price on shares of BioXcel Therapeutics from $16.00 to $26.00 and gave the company a “neutral” rating in a research report on Thursday, January 26th.

Source: https://www.americanbankingnews.com/2023/05/16/bioxcel-therapeutics-inc-nasdaqbtai-sees-significant-decline-in-short-interest.html

Hennion & Walsh Asset Management Inc. grew its stake in shares of BioXcel Therapeutics by 14.5% during the fourth quarter.

Source: https://www.dailypolitical.com/2023/05/13/bioxcel-therapeutics-nasdaqbtai-price-target-raised-to-40-00.html

On Friday, January 20th, Frank Yocca sold 50,000 shares of BioXcel Therapeutics stock.

Source: https://www.americanbankingnews.com/2023/03/19/bioxcel-therapeutics-inc-nasdaqbtai-insider-sells-19394-65-in-stock.html

Raymond James & Associates bought a new stake in shares of BioXcel Therapeutics in the first quarter worth about $229,000.

Source: https://www.etfdailynews.com/2023/02/24/connor-clark-lunn-investment-management-ltd-invests-206000-in-bioxcel-therapeutics-inc-nasdaqbtai/

SAN FRANCISCO, July 15, 2023 (GLOBE NEWSWIRE) — Hagens Berman urges BioXcel Therapeutics, Inc. investors who suffered substantial losses to submit your losses now.

Source: https://forextv.com/top-news/btai-investor-notice-hagens-berman-national-trial-attorneys-encourages-bioxcel-therapeutics-btai-investors-with-substantial-losses-to-contact-firms-attorney-securities-fraud-class-actio/